Loading
Latest filing published 06 Jan 2026 for Celldex Therapeutics, Inc., €43k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Samuel Bates Martin on record concern Celldex Therapeutics, Inc., in the capacity of finance chief. We count 8 filings; the first trade dates from 10 August 2021 and the latest from 2 January 2026.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 6 January 2026, the filings show an option exercise worth €43k in Celldex Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations